Cost-Effectiveness of Pembrolizumab for the Adjuvant Treatment of Melanoma Patients with Lymph Node Involvement Who Have Undergone Complete Resection in Argentina

INTRODUCTION: The KEYNOTE-054 trial demonstrated that adjuvant pembrolizumab improves recurrence-free survival in completely resected stage III melanoma versus watchful waiting (hazard ratio [HR] = 0.57; 98.4% confidence interval [CI], 0.43–0.74). We evaluated the cost-effectiveness of pembrolizumab...

Descripción completa

Detalles Bibliográficos
Autores principales: Wurcel, Victoria, Scherrer, Emilie, Aguiar-Ibanez, Raquel, Altuna, Juan Ignacio, Carabajal, Fernando, Jain, Shrishti, Baluni, Gargi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140053/
https://www.ncbi.nlm.nih.gov/pubmed/33624271
http://dx.doi.org/10.1007/s40487-021-00142-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140053/
https://www.ncbi.nlm.nih.gov/pubmed/33624271
http://dx.doi.org/10.1007/s40487-021-00142-8

Ejemplares similares